Allied health professionals around the country are set to benefit from a telehealth-led integration between leading telehealth software platform, Coviu, and the number one healthcare and telehealth destination, HealthEngine.
Press Release Medical Technology and Software
Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. has announced proven in vitro success with Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. Impact Biomedical and Global Research and Discovery Group Sciences (GRDG), in independent Biosafety Level 3 containment facilities, challenged its compounds with the SARS-CoV-2 virus. Equivir proved successful as a treatment, as well as a prophylactic protecting the cells from infection by the virus. Currently, there are no COVID-19 prophylactics.
Karma Yoga: Sri Krishna has also said in the Gita, has Yoga: Karmasu Kaushalam means to work efficiently. The principle of Karma Yoga is that everything we experience in the present is based on our earlier deeds. Hatha Yoga: These days the prevalence of hatha yoga has increased considerably. By doing this you can stay physically healthy and mentally peaceful.
In recent years, we have seen negative press regarding the impact of social media on mental health. However, technology can also be a great force for the good and well-being of people.
UV-C LED lamps were used to prove disinfection of COVID-19 by independent researchers at the University of Miyazaki, Japan. This study provides data on the disinfection possibilities of UV to aid the fight against COVID-19.
Agilex Biolabs, Australia's largest specialist bioanalytical laboratory for clinical trials, encouraged biotechs to consider Australia for their clinical trials during a presentation at BIO Digital 2020.
At the Helmholtz Centre for Infection Research (HZI), scientists have succeeded for the first time in detecting SARS-CoV-2 viruses using the revolutionary Cantisense(TM) technology from Digital Diagnostics AG. Application for approval of the Digid Cantisense(TM) SARS-CoV-2 Test by the FDA has been submitted. Delivery of the first point-of-care tests is planned for July.
Leading Asia-Pacific biotech specialist CRO Novotech will collaborate with Endpoints, the independent biotech news platform, for a series of webinars on the advantages of conducting clinical trials in the Asia-Pacific.
Agilex Biolabs, Australia's largest specialist bioanalytical laboratory for biotech clinical trials, is presenting the Australian Advantage including the world's most attractive rebate on clinical trials costs, at BIO Korea 2020.
In the wake of the COVID-19 crisis, Aetna Insurance has extended its coverage of cell-free DNA screening tests, previously reserved for pregnant women over 35, to all expectant mothers. While Aetna has taken an encouraging step towards safeguarding maternal health during the COVID-19 pandemic, Stand Up! 4APA urges the insurance provider to make this policy change permanent. The organization also expects other insurance providers, including UnitedHealthcare, to promptly follow Aetna's example.
Adit, a healthcare, and dental marketing company, recently introduced a new HIPAA-compliant tool called Telemed that enables doctors to provide virtual care to their patients.
Pandemic is a time when people live in fear. And pandemic is also the time when people spread rumours. When someone provides a ray of hope, people tend to hold on to it as the last straw and fake information around any crisis start spreading like a wildfire without control. The current coronavirus pandemic is no different. You surely have heard or been advised to follow a list of myths to protect yourself from the COVID-19 infection. Let us bust those here and provide you with real information so that you can follow the actual routines that can really protect you against the current novel coronavirus.
- Cyber tech company signs technology deal to supply 50M "COVI-PASS(TM)" Digital Health Passports to 15 countries - VST Enterprises signs deal with digital health technology company - Circle Pass Enterprises - to supply its patented VCode(R) technologies to create the world's most secure digital health passport - COVI-PASS(TM) - Cyber Company is committed to working closely with governments & major stakeholders to deploy safe & trusted technology solution for COVID-19 pandemic
“An intramedullary Nails (IM Nail), also known as intramedullary rod or inter-locking nail, is a metal rod pushed into the medullary cavity of a bone.”
SYDNEY, Apr 29, 2020 - (ACN Newswire) - The Asia-Pacific's largest specialist biotech CRO Novotech has been engaged for a Phase 2 COVID-19 study by biotech sponsor Karyopharm Therapeutics Inc.
GeoMap Clinical, the award-winning digital patient recruitment platform, today announced a Patient Enrollment Guarantee, ideal for sponsors wanting guaranteed patient enrollment numbers. See https://tinyurl.com/yd75bxh8.
Asia-Pacific's largest specialist biotech CRO Novotech said many countries in the region were now fast-tracking their COVID-19 clients' clinical trials with expedited review processes for treatment and vaccine candidates.
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million).
BLOCKCHAIN: A technology that took the world by storm with bitcoin in 2008 has gone on to establish itself as one of the greatest innovations since the web itself, establishing its dominance in various sectors across the globe. In this article, we discuss about blockchain in healthcare: the benefits it provides, the problems it solves, the industry trends and much more.
Path-Away(R), a plant-based natural active ingredient used in the alcohol-free NatShield(TM) hand sanitiser developed by Malaysia-based and Australia-listed Holista CollTech (ASX: HCT), has been tested by a leading U.K. bio-safety laboratory to be more than 99.99% effective against a surrogate of the COVID-19 novel coronavirus, Holista said today.
On April 15, 2020, MicroPort Scientific Corporation (Stock code: 00853) ("MicroPort"), announced that MicroPort CardioFlow Medtech Corporation ("MicroPort CardioFlow"), which is a subsidiary of MicroPort, had completed raising a new round of funds on the basis of a pre-money valuation of US$1.1 billion. The introduction of seven prominent strategic investors, who are CPE, Hillhouse Capital Management, Ltd., Lake Bleu Capital, Gamnat, China Reform Conson Soochow Overseas Fund I L.P., Gortune Artemis Limited, and 3H Health Investment Fund I, L.P., raised approximately US$130 million. After this round of fundraising, the investors will have an aggregate shareholding of 10.83% in MicroPort CardioFlow. J.P. Morgan Securities (Asia Pacific) Limited and Citigroup Global Markets Asia Limited acted as co-placement agents in the transaction.